Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions

Highlights • We model the cost effectiveness of PCV for adults with immunocompromising conditions. • We find the recommendation to be cost saving on the whole. • The recommendation saves $7 million per cohort. • This savings is largely from adults with end state renal disease. • Savings are less in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-12, Vol.31 (50), p.6011-6021
Hauptverfasser:	Cho, Bo-Hyun, Stoecker, Charles, Link-Gelles, Ruth, Moore, Matthew R
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adult adults Aged AIDS Allergy and Immunology Applied microbiology Bacteriology Biological and medical sciences cost effectiveness Cost-Benefit Analysis disease incidence Female Fundamental and applied biological sciences. Psychology HIV infections Human immunodeficiency virus Humans Immunization Immunocompromised adults Immunocompromised Host immunocompromised population Incremental cost-effectiveness kidney diseases Male Microbiology Middle Aged Miscellaneous Models, Statistical Observational studies organ transplantation PCV13 Pneumococcal Infections - economics Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - economics Pneumonia probabilistic models Public health quality-adjusted life year randomized clinical trials risk Streptococcus pneumoniae Transplants & implants United States vaccination Vaccination - economics Vaccination - methods Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We model the cost effectiveness of PCV for adults with immunocompromising conditions. • We find the recommendation to be cost saving on the whole. • The recommendation saves $7 million per cohort. • This savings is largely from adults with end state renal disease. • Savings are less in other populations with worse vaccine efficacy or serotype match.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.10.024